SAI appoints Marcel Velterop as Chief Commercial Officer

To drive business growth in three key markets of the US, Europe and APAC

SAI has promoted Marcel Velterop to Chief Commercial Officer to lead its global organisation and drive business growth over the coming years.

The Indian company has identified three key growth markets of the US, Europe and APAC (Japan, India and Israel) for its Discovery and Scale-up/Commercial businesses and will appoint three new regional integrated business development heads to deliver this growth. They will report to Velterop.

In the USA, Eric Neuffer will ensure the integration of the Discovery and Scale-up/Commercial businesses and lead the current teams.

Velterop will continue to head both the Discovery and Scale-up/Commercial efforts in Europe, while in the APAC region, a new position has been created, which is expected to be filled before the end of the 2015 financial year.

The pre-sales team will continue to report to Velterop, and the Products business to CEO Krishna Kanumuri.

You may also like

Manufacturing

Sai Life Sciences to open discovery biology facility at R&D campus

The company's client base works across a set of therapeutic areas including oncology, CNS, antivirals, and inflammation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Putting people at the core of meeting ever increasing healthcare expectation

The World Health Organization (WHO) defined health in its broader sense in its 1948 constitution as “a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity”; a substantial fraction of the waste in healthcare expenditure results from not knowing what works for particular patients in specific therapeutic indications
Manufacturing

Sai Life Sciences to exhibit at CPhI Worldwide 2017

SAI Life Sciences is a strategic contract development and manufacturing service provider, with a broad technology platform tailored to accelerate discovery, development and commercial supply of regulatory starting materials (RSM), intermediates and new chemical entities (NCE) of pharma and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Greater RSM scrutiny puts new constraints on supplier selection

The recent heightened scrutiny of Regulatory Starting Materials requires that manufacturers employ more sophisticated supplier selection criteria, argue Brian Scanlan, MD, Freedom Bioscience Solutions and Marcel Velterop, Chief Commercial Officer, SAI
Manufacturing

CPhI: SAI to emphasise RSM Quality and its new T3 facility

SAI welcomes visitors to Stand 5J10
Manufacturing

The winds of change energise evolution

NCE innovation is changing the supply chain in an unprecedented way. Couple this with a tighter regulatory framework and the payers’ search for more quality and better value and the unprepared might get blown off course, argues Marcel Veltrop, SAI Life Sciences
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Adapting to a new mindset

New industry drivers signal an opportunity for those CMOs with a more flexible approach, argues Marcel Velterop, Sr VP & Head Global Commercial Operations, SAI Life Sciences
Subscribe now